Arcutis Biotherapeutics has launched a new virtual health platform to expand access to its ZORYVE portfolio for chronic inflammatory skin diseases. The platform connects individuals with independent, board-certified dermatologists through a streamlined digital experience, targeting the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis. It is designed to complement traditional in-office care by offering a convenient alternative for those who have not seen a dermatologist or face barriers such as long wait times and geographic limitations. Participating dermatologists independently evaluate and prescribe treatment, with ZORYVE prescriptions coordinated through a national pharmacy hub for insurance support and home delivery. The launch reflects Arcutis' commitment to improving access to care beyond new treatments.
Arcutis Biotherapeutics IncLaunch of virtual health platform expands access to ZORYVE, potentially increasing prescriptions and end-customer demand.